Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROADEN: Volanesorsen in FPL
NCT02527343Phase 3Terminated
- Sponsor
- Akcea Therapeutics
- Start
- Dec 2015
- Primary completion
- Jun 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 3 trial of volanesorsen in familial partial lipodystrophy (FPLD), sponsored by Akcea Therapeutics. Started Dec 2015; status: terminated.
02
Drugs
volanesorsen
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT02527343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527343.